Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Akil Merchant et al.|Clinical Cancer Research|2023Cited by 13
Supplementary Table S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0
Supplementary Table S3 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0
Supplementary Table S5 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0